Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections

Jörg Kraus; Katrin Oppermann; Peter Wipfler; Georg Pilz; Andrea Harrer; S Afazel; Elisabeth Haschke-Becher; Alexander Kunz; Stefan Golaszewski; Wolfgang Staffen; G Ladurner

Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections

Jörg Kraus, Katrin Oppermann, Peter Wipfler, Georg Pilz, Andrea Harrer, S Afazel, Elisabeth Haschke-Becher, Alexander Kunz, Stefan Golaszewski, Wolfgang Staffen, G Ladurner

Department of Neurology

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	A416-A416
Journal	NEUROLOGY
Volume	74
Issue number	9
Publication status	Published - 2010
Event	62nd Annual Meeting of the American-Academy-of-Neurology - Toronto, CANADA Duration: 10 Apr 2010 → 17 Apr 2010

Cite this

Kraus, J., Oppermann, K., Wipfler, P., Pilz, G., Harrer, A., Afazel, S., Haschke-Becher, E., Kunz, A., Golaszewski, S., Staffen, W., & Ladurner, G. (2010). Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections. NEUROLOGY , 74(9), A416-A416.

Kraus, Jörg ; Oppermann, Katrin ; Wipfler, Peter et al. / Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections. In: NEUROLOGY 2010 ; Vol. 74, No. 9. pp. A416-A416.

@article{be6fb3f69ab34eafa45f6040de9654b7,

title = "Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections",

author = "J{\"o}rg Kraus and Katrin Oppermann and Peter Wipfler and Georg Pilz and Andrea Harrer and S Afazel and Elisabeth Haschke-Becher and Alexander Kunz and Stefan Golaszewski and Wolfgang Staffen and G Ladurner",

year = "2010",

language = "English",

volume = "74",

pages = "A416--A416",

journal = "NEUROLOGY ",

issn = "0028-3878",

publisher = "Lippincott Williams & Wilkins ",

number = "9",

note = "62nd Annual Meeting of the American-Academy-of-Neurology ; Conference date: 10-04-2010 Through 17-04-2010",

}

Kraus, J, Oppermann, K, Wipfler, P , Pilz, G , Harrer, A, Afazel, S, Haschke-Becher, E, Kunz, A, Golaszewski, S, Staffen, W & Ladurner, G 2010, 'Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections', NEUROLOGY , vol. 74, no. 9, pp. A416-A416.

Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections. / Kraus, Jörg; Oppermann, Katrin; Wipfler, Peter et al.
In: NEUROLOGY , Vol. 74, No. 9, 2010, p. A416-A416.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections

AU - Kraus, Jörg

AU - Oppermann, Katrin

AU - Wipfler, Peter

AU - Pilz, Georg

AU - Harrer, Andrea

AU - Afazel, S

AU - Haschke-Becher, Elisabeth

AU - Kunz, Alexander

AU - Golaszewski, Stefan

AU - Staffen, Wolfgang

AU - Ladurner, G

PY - 2010

Y1 - 2010

M3 - Abstract (Journal)

SN - 0028-3878

VL - 74

SP - A416-A416

JO - NEUROLOGY

JF - NEUROLOGY

IS - 9

T2 - 62nd Annual Meeting of the American-Academy-of-Neurology

Y2 - 10 April 2010 through 17 April 2010

ER -

Kraus J, Oppermann K, Wipfler P , Pilz G , Harrer A, Afazel S et al. Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections. NEUROLOGY . 2010;74(9):A416-A416.